Logo video2dn
  • Сохранить видео с ютуба
  • Категории
    • Музыка
    • Кино и Анимация
    • Автомобили
    • Животные
    • Спорт
    • Путешествия
    • Игры
    • Люди и Блоги
    • Юмор
    • Развлечения
    • Новости и Политика
    • Howto и Стиль
    • Diy своими руками
    • Образование
    • Наука и Технологии
    • Некоммерческие Организации
  • О сайте

Видео ютуба по тегу Event: Aacr 2025

AACR 2025: 7,000+ Sessions & Breakthroughs in Oncology Research! 🚀
AACR 2025: 7,000+ Sessions & Breakthroughs in Oncology Research! 🚀
Отчет AACR о прогрессе в борьбе с раком за 2025 год
Отчет AACR о прогрессе в борьбе с раком за 2025 год
Curvia at AACR 2025 Conference in Chicago, USA.
Curvia at AACR 2025 Conference in Chicago, USA.
Inocras AACR 2025 MRD
Inocras AACR 2025 MRD
AACR Pediatric Cancer Progress Report 2025: Congressional Briefing Video
AACR Pediatric Cancer Progress Report 2025: Congressional Briefing Video
AACR [2025] IO: The Future of Immunotherapy Unveiled in LA with Antoni Ribas, MD UCLA Cancer Center
AACR [2025] IO: The Future of Immunotherapy Unveiled in LA with Antoni Ribas, MD UCLA Cancer Center
047: Live from the AACR Annual Meeting 2025 - Stories from the Frontlines of Cancer Research–Part 1
047: Live from the AACR Annual Meeting 2025 - Stories from the Frontlines of Cancer Research–Part 1
Biointron at AACR Annual Meeting 2025 in Chicago
Biointron at AACR Annual Meeting 2025 in Chicago
AACR Douglas Hanahan, PhD, Wins 2025 Pezcoller Foundation-AACR Award for Cancer Research Excellence
AACR Douglas Hanahan, PhD, Wins 2025 Pezcoller Foundation-AACR Award for Cancer Research Excellence
Insights Corner: Highlights from the AACR Annual Meeting 2025
Insights Corner: Highlights from the AACR Annual Meeting 2025
AACR Annual Meeting 2025: Unifying Cancer Science and Medicine: A Continuum of Innovation for Impact
AACR Annual Meeting 2025: Unifying Cancer Science and Medicine: A Continuum of Innovation for Impact
Zongertinib in HER2-Mutant NSCLC: 71% Response Rate from Beamion LUNG-1 Trial | AACR 2025
Zongertinib in HER2-Mutant NSCLC: 71% Response Rate from Beamion LUNG-1 Trial | AACR 2025
Addition of pembrolizumab to standard care shows promising results in advanced head and neck cancer
Addition of pembrolizumab to standard care shows promising results in advanced head and neck cancer
AACR Special Conference in Cancer Research: Fusion-Positive Cancers.
AACR Special Conference in Cancer Research: Fusion-Positive Cancers.
KEYTRUDA Pembrolizumab KEYNOTE-689 Phase 3 Update in resectable LA-HNSCC  | AACR 2025 News
KEYTRUDA Pembrolizumab KEYNOTE-689 Phase 3 Update in resectable LA-HNSCC | AACR 2025 News
Ключевые новости с конференции AACR и другие интересные факты за 2024 год
Ключевые новости с конференции AACR и другие интересные факты за 2024 год
Следующая страница»
  • О нас
  • Контакты
  • Отказ от ответственности - Disclaimer
  • Условия использования сайта - TOS
  • Политика конфиденциальности

video2dn Copyright © 2023 - 2025

Контакты для правообладателей [email protected]